"Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder (ILR)" (CRYPTONITE)
Observational Study on Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder
STUDY TYPE:
Prospective, national , multicenter, and observational study.
OBJECTIVE:
To assess the incidence of AF in patients with cryptogenic stroke who have implanted an AF detection device during a period of 2 years.
DEVICE:
Reveal XT 9529 (SQDM)
SAMPLE SIZE AND STUDY DURATION:
100 patients enrolled which will be followed during a period of 2 years.
調査の概要
状態
状態
詳細な説明
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Ricardo Ruiz-Granell, MD, PhD
- 電話番号:0034 963862658
- メール:ruiz_ric@gva.es
研究連絡先のバックアップ
- 名前:Arcadio García-Alberola, MD, PhD
- メール:arcadi@secardiologia.es
研究場所
-
-
-
Murcia、スペイン、30120
- Hospital Universitario Virgen de la Arrixaca
-
Valencia、スペイン、46010
- Hospital Clínico Universitario de Valencia
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
All patients included must meet one of these two conditions:
- Patient presenting with an episode of transient ischemic attack (TIA) of cryptogenic origin with neurological symptoms of less than 24h of evolution and negative neuroimaging.
- First episode of ischaemic stroke with cryptogenic etiology following TOAST criteria
All patients must meet all of the following:
- The patient has been implanted an ILR within 30 days after qualifying event
- Age between 45-85 years
- No stenosis >50% in any arterial vessel corresponding to the affected territory
- Normal Echocardiography
- Normal 24 hours EKG Holter recording
- Absence of Patent Foramen Ovale through transcranial doppler (or transesophageal echocardiography)
- Acceptance and signature of Patient Informed Consent.
Exclusion Criteria:
All patients included cannot meet any of the following conditions:
- Recurrent stroke or TIA
- Stroke or TIA with determined etiology according to TOAST criteria.
- Anticoagulation indication at the time of enrollment in the study.
- Total contraindication for anticoagulation therapy
- Atrial fibrillation detection prior to enrollment
- Severe cognitive impairment or dementia
- Patient unable to be followed up
- Patients enrolled in another clinical trial
- Patients with life expectancy of less than 1 year
- Pregnancy
研究計画
研究はどのように設計されていますか?
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Study group
Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
First AF episode detected by the implantable loop recorder in patients that had a cryptogenic stroke. An AF episode will be considered an AF episode that lasts at least 2 minutes.
時間枠:Patients will be followed up during two years, regardless of reaching or not the primary endpoint.
|
Patients will be followed up during two years, regardless of reaching or not the primary endpoint.
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
All subsequent AF episodes detected by the ILR after primary outcome (AF burden)
時間枠:Patients will be followed up during two years
|
Patients will be followed up during two years
|
|
AF episodes detected by external monitoring
時間枠:Patients will be followed up during two years
|
Patients will be followed up during two years
|
|
Presence of stroke, recurrent TIA, or silent infarction in neuroimaging
時間枠:Patients will be followed up during two years
|
Patients will be followed up during two years
|
|
Changes in anticoagulant therapy
時間枠:Patients will be followed up during two years
|
Patients will be followed up during two years
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Ricardo Ruiz-Granell, MD, Phd、Hospital Clínico Universitario de Valencia
- スタディチェア:Arcadio Garcia-Alberola, MD, PhD、Hospital Universitario Virgen de la Arrixaca
- スタディチェア:Ana Morales, MD、Hospital Universitario Virgen de la Arrixaca
- スタディチェア:Alejandro Ponz, MD、Hospital Clínico Universitario de Valencia
出版物と役立つリンク
一般刊行物
- Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Kannel WB, Wolf PA. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA. 2006 Dec 27;296(24):2939-46. doi: 10.1001/jama.296.24.2939.
- Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 Jan;24(1):35-41. doi: 10.1161/01.str.24.1.35.
- Solano A, Menozzi C, Maggi R, Donateo P, Bottoni N, Lolli G, Tomasi C, Croci F, Oddone D, Puggioni E, Brignole M. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease. Eur Heart J. 2004 Jul;25(13):1116-9. doi: 10.1016/j.ehj.2004.05.013.
- Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke. 2004 Jul;35(7):1647-51. doi: 10.1161/01.STR.0000131269.69502.d9. Epub 2004 May 20.
- Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF, Hansen MD. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999 Jul 13;53(1):126-31. doi: 10.1212/wnl.53.1.126.
- Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989 Apr;25(4):382-90. doi: 10.1002/ana.410250410.
- Douen AG, Pageau N, Medic S. Serial electrocardiographic assessments significantly improve detection of atrial fibrillation 2.6-fold in patients with acute stroke. Stroke. 2008 Feb;39(2):480-2. doi: 10.1161/STROKEAHA.107.492595. Epub 2008 Jan 3.
- Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke. 2007 Nov;38(11):2935-40. doi: 10.1161/STROKEAHA.106.478685. Epub 2007 Sep 27.
- Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007 Feb 6;115(5):e69-171. doi: 10.1161/CIRCULATIONAHA.106.179918. Epub 2006 Dec 28. No abstract available.
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (推定)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。